BIOINVENT INTERNATIONAL AB “2023 was a landmark year for
Events in the fourth quarter
- Positive data from clinical Phase 1/2a trial of BI-1808 as single agent were presented at SITC
- Preclinical data providing clear evidence of the potential of anti-TNFR2 antibody BI-1910 were presented at SITC
- Positive first clinical data on anti-FcyRIIB antibody BI-1607 presented at the San Antonio Breast Cancer Symposium
- First patient enrolled in Phase 1/2a clinical trial with TNFR2 antibody BI-1910
BioInvent and Transgene announced that the first patient had been treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)
Events after the end of the period
- Supply agreement signed with
AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence BioInvent regained the rights to immuno-oncology targets fromExelixis
Earlier during 2023, in brief
- (R)
BioInvent selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and receivedUSD 3 million strategic equity investment - (R) A fourth complete response announced in Phase 1/2 trial with BI-1206 in non-Hodgkin’s lymphoma
- Management strengthened with the appointment of
Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs - (R)
BioInvent and Transgene reported positive Phase 1a data on oncolytic virus BT-001 in solid tumors - (R) Additional efficacy data announced from intravenous part of Phase 1/2 trial with BI-1206 in solid tumors
- (R) Strong interim safety data and early signs of efficacy reported in Phase 1/2a trial with anti-TNFR2 antibody BI-1808 in advanced malignancies
- Research milestone event achieved in the collaboration with
Exelixis , triggering aUSD 1 million milestone payment
(R)= Regulatory event
Financial information
Fourth quarter 2023
- Net sales
SEK 15.3 (20.6) million. - Profit/loss after tax
SEK -97.2 (-78.3) million. - Profit/loss after tax per share before and after dilution
SEK -1.48 (-1.21). - Cash flow from operating activities
SEK -72.4 (-71.7) million.
January –
- Net sales
SEK 71.5 (326.1) million. - Profit/loss after tax
SEK -330.3 (-42.5) million. - Profit/loss after tax per share before and after dilution
SEK -5.02 (-0.69). - Cash flow from operating activities
SEK -341.7 (-41.2) million. - Liquid funds, current and long-term investments as of
December 31, 2023 :SEK 1,283.0 (1,593.6) million.
Note to reader. Figures in parentheses refer to the outcome for the corresponding period in the preceding year.
Read the complete report in the attached pdf.
INVITATION TO PRESENTATION OF YEAR-END REPORT 2023
BioInvent’s CEO
When:
Listen to the presentation webcast: https://financialhearings.com/event/48630
To participate via teleconference, please register via the following link: https://conference.financialhearings.com/teleconference/?id=50048630.
Upon registration, a phone number and conference ID for the conference call will be provided. You can ask questions verbally via the telephone conference.
The conference call will be made available on the company website after the call.
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on the social media platform X: @BioInvent.
For further information, please contact:
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
© Modular Finance, source
